Medmain

Medmain is a technology company.

Active

Updated: Dec 9, 2025 ·

Recent News & Mentions

May 1, 2025FundingMedmain - Venture Round Apr 1, 2024FundingMedmain - Series A Aug 1, 2020FundingMedmain - Series A

Financial History

Medmain has raised $18.0M across 3 funding rounds. Most recently, it raised $3.0M Venture Round in May 2025.

Total Raised

$18.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
May 1, 2025	$3.0M Venture Round	Bow Capital, Buckley Ventures, DVx Ventures, Eunoia Capital Partners, Goodwater Capital, i/o Ventures, Launch Capital, Liquid 2 Ventures, Niu Ventures, Oak HC/FT, Plug & Play Ventures, Vera Equity, Brandon Krieg, Immad Akhund, Jay Vijayan
Apr 1, 2024	$5.0M Series A	Pioneer Fund
Aug 1, 2020	$10.0M Series A

Financial History

Medmain has raised $18.0M across 3 funding rounds.

Total Raised

$18.0M

Valuation

N/A

Deep Dive

High-Level Overview

Medmain Inc. is a Japanese medtech startup founded in 2018, headquartered in Fukuoka with offices in Tokyo and the US, specializing in AI-driven pathology solutions to enhance healthcare accessibility worldwide.[1][2][3] The company develops PidPort, a cloud-based AI system for pathological image diagnosis using deep learning for precise screening, telepathology, and cloud storage of specimens, alongside Medteria, a cloud service for medical students.[1][2] It serves hospitals, physicians, pathologists, and medical students, addressing challenges like slow diagnosis workflows, limited remote access, and storage issues in pathology by enabling faster, objective AI-assisted analysis and global collaboration.[1][2][3] With revenue under $5 million and recent growth including US market entry via accelerators and implementations in Vietnam, Medmain shows momentum through international expansion and investments like from Plug and Play.[1][2][4]

Origin Story

Medmain was founded on January 11, 2018, by CEO Osamu Iizuka, a Kyushu University School of Medicine graduate with expertise in machine learning, deep learning, and web development.[3] After working as a web engineer in a startup and winning first place at a Silicon Valley pitch competition, Iizuka teamed up with a few Kyushu University members—including engineers and pathologists from diverse nationalities—to launch the company.[2][3] The idea emerged from combining medical pathology knowledge with AI to digitize and accelerate image diagnosis, starting with PidPort to support practitioners globally.[1][2][3] Early traction included product development focused on deep learning for pathology, leading to certifications like ISMS (ISO/IEC 27001:2022) in 2024 and selections for programs like the US Market Gateway Accelerator in 2023.[1][3]

Core Differentiators

Medmain stands out in digital pathology through these key strengths:

AI-Powered Precision and Speed: PidPort uses proprietary deep learning for instantaneous, highly accurate screening of pathologic tissues and cells, easing daily workflows as an assistant to pathologists.[1][2]
Telepathology and Global Connectivity: Enables remote diagnosis via a worldwide network of practitioners, supporting timely consultations regardless of location (availability varies by region).[2]
Cloud Infrastructure: Provides secure, scalable storage for digitized images and case histories, eliminating physical deterioration and space concerns.[2][3]
Dual Offerings for Pros and Students: Combines PidPort for professionals with Medteria for education, broadening impact in healthcare training and practice.[1]
Quality and Agility Focus: Emphasizes customer prioritization, rapid development without quality compromise, and proactive innovation, backed by ISO certifications and a multidisciplinary team.[3]

Role in the Broader Tech Landscape

Medmain rides the digital pathology and AI-in-healthcare wave, transforming traditional microscope-based diagnosis into cloud-AI hybrids amid rising demand for faster, remote-capable tools post-COVID.[1][2][5] Timing aligns with global medtech growth, including Asia's digital health push and US expansion opportunities, as seen in their 2023 accelerator selection and Vietnam hospital implementation.[1][2] Market forces like pathologist shortages, aging populations in Japan, and regulatory approvals for AI diagnostics favor them, while investments from firms like Plug and Play fuel scaling.[4] They influence the ecosystem by partnering with practitioners worldwide, standardizing AI-assisted pathology, and participating in events like the Asian Society of Digital Pathology Congress, democratizing access in underserved regions.[2]

Quick Take & Future Outlook

Medmain is poised for accelerated global rollout of PidPort, targeting more US and ASEAN markets with recent Vietnam success and US presence signaling momentum.[1][2] Trends like AI regulatory harmonization, telehealth expansion, and multimodal diagnostics will shape their path, potentially integrating with broader EHR systems. Their influence may evolve from niche innovator to key enabler of accessible pathology, amplifying impact as AI maturity grows—building on their mission to deliver medical services anywhere, anytime through technology.[3]

Sources

Frequently Asked Questions

How much funding has Medmain raised?

Medmain has raised $18.0M in total across 3 funding rounds.

Who are Medmain's investors?

Medmain's investors include Bow Capital, Buckley Ventures, DVx Ventures, Eunoia Capital Partners, Goodwater Capital, i/o Ventures, Launch Capital, Liquid 2 Ventures, Niu Ventures, Oak HC/FT, Plug & Play Ventures, Vera Equity.